S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:TBIO

Translate Bio - TBIO Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$37.36
$37.36
50-Day Range
$36.89
$37.77
52-Week Range
$11.91
$37.99
Volume
10 shs
Average Volume
1.66 million shs
Market Capitalization
$2.82 billion
P/E Ratio
66.71
Dividend Yield
N/A
Price Target
N/A
TBIO stock logo

About Translate Bio (NASDAQ:TBIO) Stock

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Receive TBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Translate Bio and its competitors with MarketBeat's FREE daily newsletter.

TBIO Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Translate Bio, Inc. (TBIO)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Pilgrim’s Pride and Icosavax See Activist Action
Inside Sanofi's $3.2B Translate Bio Buyout
TRANSLATE BIO INVESTOR ALERT by the Former...
Why Translate Bio Stock Soared Today
See More Headlines

Receive TBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Translate Bio and its competitors with MarketBeat's FREE daily newsletter.

TBIO Company Calendar

Last Earnings
8/04/2021
Today
8/19/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBIO
Fax
N/A
Employees
122
Year Founded
N/A

Profitability

Net Income
$-53,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$138.81 million
Book Value
$4.80 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.82 billion
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Ilan Danieli
    Chief Executive Officer & Director
  • Ahmed Zaki Sabet
    Chief Operating Officer
  • Carl R. Iberger
    Chief Financial Officer
  • Ayman A. Mohamed
    Vice President-Research & Development
  • Ori Karev
    Chief Strategy Officer













TBIO Stock - Frequently Asked Questions

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) announced its quarterly earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.44. The company earned $72.65 million during the quarter, compared to the consensus estimate of $38.23 million. Translate Bio had a net margin of 17.97% and a trailing twelve-month return on equity of 1.50%.

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $37.36.

How much money does Translate Bio make?

Translate Bio (NASDAQ:TBIO) has a market capitalization of $2.82 billion and generates $138.81 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Translate Bio have?

The company employs 122 workers across the globe.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.translate.bio. The company can be reached via phone at (203) 787-7888.

This page (NASDAQ:TBIO) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.